Cost-optimized placenta-targeted nanoparticle for localized immune cloaking in recurrent pregnancy loss.

Abstract: Recurrent pregnancy loss (RPL) is defined as the occurrence of two or more consecutive miscarriages and affects approximately 1-2% of reproductive-aged couples. Immune-mediated factors at the maternal-fetal interface are increasingly recognized as significant contributors to otherwise unexplained RPL. Current therapeutic approaches largely rely on systemic immunosuppression, which demonstrates limited efficacy and imposes substantial maternal risks. Here, we propose a drug-free, placenta-targeted nanoparticle (NP) system for localized immune cloaking utilizing well-characterized, cost-effective materials. The core design consists of a biodegradable PLGA matrix, a lipid-polyethylene glycol (PEG) stealth layer, superparamagnetic iron oxide nanoparticles (SPIONs) for imaging, and placental-homing peptides for targeted delivery. The mechanisms of immune cloaking may include PEG stealth, red blood cell membrane coating, or immunomodulatory ligands to induce site-specific immune tolerance while avoiding the adverse effects associated with systemic immunosuppression. We discuss material accessibility, feasibility of large-scale manufacture, and the preclinical evidence base to be developed. Finally, we outline regulatory pathways and prospective clinical trial designs. This localized NP-based treatment may offer a significant reduction in RPL incidence by promoting targeted maternal-fetal immune tolerance while addressing the safety and cost limitations inherent to current broad-spectrum immunotherapies. Lay summary: Miscarriage is heartbreaking and a growing issue that many families deal with. For some women, it occurs repeatedly for no apparent reason. One of the major causes is thought to be an overreactive immune response, in which the immune system of the mother unintentionally targets the growing fetus. Currently, medications that suppress the entire immune system, also known as immunosuppressive treatments, are occasionally administered to women who have experienced repeated miscarriage. These therapies may have systemic effects on the whole body, can be costly, and put the mother at higher risk of developing serious adverse events. Our study proposes a new, secure option. We recommend using nanoparticles, tiny particles specifically engineered to reach the placenta, and give details regarding the design, safety and efficacy protocols, and the road map to make this product commercially available. Once in place, the nanoparticles can help establish a secure environment where the fetus can grow safely by shielding the fetus from the mothers' immune system. Nanoparticles are a growing treatment option in many fields and can also be used in reproductive medicine to help families who have suffered recurrent miscarriages. In addition, this could decrease the burden of miscarriage on both families and the health care system by improving pregnancy outcomes and reducing the need for dangerous medications.